Skip to main content

Table 2 The survival time, depending on the demographic and clinical factors (multivariate analysis)

From: Quality of life during chemotherapy, hormonotherapy or antiHER2 therapy of patients with advanced, metastatic breast cancer in clinical practice

VariableRisk ratio (95%Cl)p
ECOG performance status1,54 (1,21-1,98)0,01
Type of therapy0,82 (0,61-1,02)0,08
Age0,91 (0,74-1,16)0,11
Education1,01 (0,81-1,21)0,94
Place of residence1,10 (0,78-1,42)0,71
Treatment centre1,05 (0,75-1,45)0,88
Smoking status0,91 (0,80-1,02)0,19
Response to treatment0,64 (0,44-0,83)< 0,001